Overview

Evaluation of Dapagliflozin Taken Twice-daily

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5 mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is beneficial in diabetes treatment, and if so, how it compares to treatment with metformin alone.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Dapagliflozin
Metformin